Compare PSKY & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PSKY | RPRX |
|---|---|---|
| Founded | 1914 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.2B | 16.7B |
| IPO Year | N/A | 2020 |
| Metric | PSKY | RPRX |
|---|---|---|
| Price | $11.90 | $40.54 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 12 | 4 |
| Target Price | $14.08 | ★ $45.75 |
| AVG Volume (30 Days) | ★ 6.1M | 3.4M |
| Earning Date | 02-26-2026 | 02-11-2026 |
| Dividend Yield | 1.71% | ★ 2.33% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.75 |
| Revenue | ★ $28,727,000,000.00 | $2,349,844,000.00 |
| Revenue This Year | $1.00 | $37.66 |
| Revenue Next Year | $3.57 | $2.34 |
| P/E Ratio | ★ N/A | $23.06 |
| Revenue Growth | N/A | ★ 3.70 |
| 52 Week Low | $9.95 | $29.66 |
| 52 Week High | $20.86 | $41.70 |
| Indicator | PSKY | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 34.29 | 59.05 |
| Support Level | $11.42 | $38.86 |
| Resistance Level | $11.94 | $40.58 |
| Average True Range (ATR) | 0.29 | 0.76 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 30.45 | 58.63 |
Paramount Global operates in three global business segments: TV media, filmed entertainment, and direct to consumer. The TV media business includes television production studios and various broadcast and cable networks, including CBS, 15 owned CBS affiliates, Paramount, Nickelodeon, MTV, BET, and VH1. Filmed entertainment consists multiple film studios, most importantly Paramount Pictures. The film studios produce and distribute movies that they license to movie theaters and other media outlets. Direct to consumer includes the Paramount+, Pluto TV, and BET+ streaming services. Much of the content on Paramount's streaming platforms is created by the production studios housed within the firm's other two business segments.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.